Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 12:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Nephrotic Syndrome, Proteinuria, Autoimmune Disease, Glomerular Disease, Membranous Glomerulonephritis
Interventions
Rituximab Infusion, Oral Cyclosporine
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced May 22, 2026, 12:39 AM EDT
Conditions
pMN, IgAN, Nephrotic Syndrome, MCD, FSGS
Interventions
Atacicept
Drug
Lead sponsor
Vera Therapeutics, Inc.
Industry
Eligibility
10 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Brisbane, California
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced May 22, 2026, 12:39 AM EDT
Conditions
Proteinuria, Idiopathic Membranous Nephropathy
Interventions
Repository Corticotropin Injection, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
14
States / cities
Sacramento, California • Stanford, California • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced May 22, 2026, 12:39 AM EDT
Conditions
Childhood Idiopathic Nephrotic Syndrome
Interventions
Obinutuzumab, MMF, Prednisone, Methylprednisolone, Acetaminophen/ Paracetamol, Diphenhydramine Hydrochloride
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 25 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
10
States / cities
Palo Alto, California • Hollywood, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced May 22, 2026, 12:39 AM EDT
Conditions
Idiopathic Nephrotic Syndrome
Interventions
Standard of Care, UrApp
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
3
States / cities
Atlanta, Georgia • Minneapolis, Minnesota • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced May 22, 2026, 12:39 AM EDT
Completed No phase listed Observational
Conditions
Kidney Disease, Glomerular Disease, Idiopathic Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, Collapsing Glomerulopathy
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
2 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced May 22, 2026, 12:39 AM EDT
Conditions
Nephrotic Syndrome
Interventions
ADX-629
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
11
States / cities
Northridge, California • Aurora, Colorado • Lauderdale Lakes, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced May 22, 2026, 12:39 AM EDT
Recruiting Not applicable Interventional
Conditions
Nephrotic Syndrome in Children, Focal Segmental Glomerulosclerosis, Minimal Change Disease, Minimal Change Nephrotic Syndrome, Membranous Nephropathy, FSGS, MCD, MCD - Minimal Change Disease, Alport Syndrome
Interventions
Communication
Other
Lead sponsor
University of Michigan
Other
Eligibility
1 Year to 80 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
16
States / cities
Atlanta, Georgia • Chicago, Illinois • Kansas City, Kansas + 11 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced May 22, 2026, 12:39 AM EDT
Conditions
Glomerulosclerosis, Focal Segmental
Interventions
Losmapimod
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
8
States / cities
Los Angeles, California • Stanford, California • New Orleans, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2017 · Synced May 22, 2026, 12:39 AM EDT
Conditions
Idiopathic Nephrotic Syndrome, Frequently Relapsing Nephrotic Syndrome
Interventions
Transcutaneous Auricular Vagus Nerve (taVNS) stimulation
Device
Lead sponsor
Northwell Health
Other
Eligibility
2 Years to 21 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced May 22, 2026, 12:39 AM EDT
Conditions
Nephrotic Syndrome
Interventions
Prednisolone
Drug
Lead sponsor
All India Institute of Medical Sciences
Other
Eligibility
1 Year to 4 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
4
States / cities
Los Angeles, California • Stanford, California • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced May 22, 2026, 12:39 AM EDT
Conditions
Nephrotic Syndrome With Edema (Diagnosis), Minimal Change Nephrotic Syndrome, Focal Segmental Glomerulosclerosis (FSGS), Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy
Interventions
Serum and renal tissue analysis
Other
Lead sponsor
Meyer Children's Hospital IRCCS
Other
Eligibility
0 Years to 99 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2036
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced May 22, 2026, 12:39 AM EDT
Conditions
Fluid Overload, Glomerulosclerosis, Focal Segmental, Edema, Membranous Nephropathy, Minimal Change Disease, Minimal Change Nephrotic Syndrome, IgM Nephropathy, Nephrotic Syndrome, Glomerular Disease, Nephrotic Syndrome, Minimal Change, Nephrotic Syndrome in Children, Nephrotic Syndrome With Edema (Diagnosis), FSGS
Interventions
Interview
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
2 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced May 22, 2026, 12:39 AM EDT
Conditions
Membranous Glomerulonephritis, Lupus Membranous Nepropathy
Interventions
Sirolimus
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
13 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced May 22, 2026, 12:39 AM EDT